[go: up one dir, main page]

WO2023250431A3 - Multi-cyclic irak and flt3 inhibiting compounds and uses thereof - Google Patents

Multi-cyclic irak and flt3 inhibiting compounds and uses thereof Download PDF

Info

Publication number
WO2023250431A3
WO2023250431A3 PCT/US2023/068897 US2023068897W WO2023250431A3 WO 2023250431 A3 WO2023250431 A3 WO 2023250431A3 US 2023068897 W US2023068897 W US 2023068897W WO 2023250431 A3 WO2023250431 A3 WO 2023250431A3
Authority
WO
WIPO (PCT)
Prior art keywords
flt3
irak
compounds
compositions
inhibiting compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/068897
Other languages
French (fr)
Other versions
WO2023250431A9 (en
WO2023250431A2 (en
Inventor
Craig Joseph THOMAS
Scott Bryan HOYT
Daniel T. STARCZYNOWSKI
Jan Susan Rosenbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
US Department of Health and Human Services
Kurome Therapeutics Inc
Original Assignee
Cincinnati Childrens Hospital Medical Center
US Department of Health and Human Services
Kurome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center, US Department of Health and Human Services, Kurome Therapeutics Inc filed Critical Cincinnati Childrens Hospital Medical Center
Publication of WO2023250431A2 publication Critical patent/WO2023250431A2/en
Publication of WO2023250431A3 publication Critical patent/WO2023250431A3/en
Anticipated expiration legal-status Critical
Publication of WO2023250431A9 publication Critical patent/WO2023250431A9/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Some embodiments of the disclosure include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.
PCT/US2023/068897 2022-06-22 2023-06-22 Multi-cyclic irak and flt3 inhibiting compounds and uses thereof Ceased WO2023250431A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263354398P 2022-06-22 2022-06-22
US63/354,398 2022-06-22

Publications (3)

Publication Number Publication Date
WO2023250431A2 WO2023250431A2 (en) 2023-12-28
WO2023250431A3 true WO2023250431A3 (en) 2024-02-08
WO2023250431A9 WO2023250431A9 (en) 2025-03-06

Family

ID=89380511

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/068897 Ceased WO2023250431A2 (en) 2022-06-22 2023-06-22 Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Country Status (1)

Country Link
WO (1) WO2023250431A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709468B2 (en) * 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
WO2012052745A1 (en) * 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
WO2014210255A1 (en) * 2013-06-26 2014-12-31 Abbvie Inc. Primary carboxamides as btk inhibitors
WO2018038988A2 (en) * 2016-08-17 2018-03-01 Children's Hospital Medical Center Compounds, compositions, methods for treating diseases, and methods for preparing compounds
US20210179625A1 (en) * 2017-04-12 2021-06-17 Magenta Therapeutics Inc. Aryl hydrocarbon receptor antagonists and uses thereof
WO2022140647A1 (en) * 2020-12-23 2022-06-30 Children's Hospital Medical Center Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709468B2 (en) * 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
WO2012052745A1 (en) * 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
WO2014210255A1 (en) * 2013-06-26 2014-12-31 Abbvie Inc. Primary carboxamides as btk inhibitors
WO2018038988A2 (en) * 2016-08-17 2018-03-01 Children's Hospital Medical Center Compounds, compositions, methods for treating diseases, and methods for preparing compounds
US20210179625A1 (en) * 2017-04-12 2021-06-17 Magenta Therapeutics Inc. Aryl hydrocarbon receptor antagonists and uses thereof
WO2022140647A1 (en) * 2020-12-23 2022-06-30 Children's Hospital Medical Center Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE PubChem Compound ANONYMOUS : "3-Pyridin-2-ylimidazo[1,2-a]pyrazine", XP093138463, retrieved from PubChem *

Also Published As

Publication number Publication date
WO2023250431A9 (en) 2025-03-06
WO2023250431A2 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
MX2023006937A (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof.
EP4548918A3 (en) Tricyclic compounds as inhibitors of kras
Luongo et al. Possible therapeutic effects of ozone mixture on hypoxia in tumor development
ES2617689T3 (en) Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent
NI200400014A (en) ARILUREA COMPOUNDS IN COMBINATION WITH OTHER CITOSTATIC OR CYTOTOXIC AGENTS TO TREAT HUMAN CANCER
MX2023001997A (en) Bicyclic compounds, compositions and use thereof.
MX2024001193A (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof.
Senkevitch et al. Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations
MY112405A (en) Method of tumer treatment.
DE69434416D1 (en) PREPARATIONS ON PURINBASIS
MXPA05007352A (en) Diazepinoindole derivatives as kinase inhibitors.
HK1045462B (en) Combined preparations comprising morpholine anthracyclines and anticancer agent
WO2021222542A8 (en) 5-amino-2-piperidinon-3-yl-1-oxoisoindoline derivatives for degradation of ikzf2 degraders
WO2023245123A3 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2023150601A3 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
MX2023006938A (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof.
IL197513A0 (en) Pyrazolopyrimidine derivatives and pharmaceutical compositions containing the same
Köpf-Maier et al. Activity of titanocene dihalides against a human colon carcinoma heterotransplanted to athymic mice
RU2008138534A (en) PHARMACEUTICAL COMBINATION FOR TREATMENT AND / OR CHEMOSENSIBILIZATION OF TUMORS RESISTANT TO ANTICANCERS
WO2023250431A3 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2024163764A3 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
NO891122L (en) PLATINO COORDINATION COMPOUNDS AND USING THE COMPOUNDS IN CHEMICAL THERAPY.
WO2023141360A3 (en) Anti-b7-h3 compounds and methods of use
Bruserud et al. High-dose etoposide in allogeneic stem cell transplantation
MX2024000610A (en) Therapeutic compounds and methods.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23828048

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23828048

Country of ref document: EP

Kind code of ref document: A2